Skip to main content

Table 1 Patient demographics and clinical characteristics

From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Characteristic
Age, Mean, y (range) 55 (30–64)
Sex
 Male, No. (%) 10 (59)
 Female, No. (%) 7 (41)
Stage, No. (%)
 Unresectable III 8 (47)
 M1a 2 (12)
 M1b 1 (6)
 M1c 6 (35)
ECOG PS, No. (%)
 0 15 (88)
 1 2 (12)
LDH, No. (%)
 Normal 12 (71)
 >ULN 5 (29)
Mutation status
 BRAF V600E/K 12 (71)
 C-KIT 1 (6)
 NRAS Q61R 1 (6)
 WT 3 (18)
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, No number, ULN upper limit of normal